Liaoning Chengda Biotechnology Co. Ltd. A

Chengda Bio released its 2026 interim report, with net profit attributable to the parent company of 33.28 million yuan, a decrease of 72.79% compared with the same period last year. The company's total operating revenue was 677 million yuan, a year-on-year decrease of 4.18%; net cash inflow from operating activities was 70.76 million yuan, down 44.05% year-on-year. The company's latest gross margin was 74.24%, a decrease of 4.86 percentage points from the same period last year; diluted earnings per share was 0.08 yuan, down 73.33% year-on-year.

Chengda Bio released its 2026 half-year report, showing net profit attributable to the parent of 33.28 million yuan, down 72.8% year on year. Operating revenue was 677 million yuan, down 4.2% year on year. Net profit attributable to the parent after deducting non-recurring items was 26.83 million yuan, down 73.7% year on year. Net operating cash flow was 70.76 million yuan, down 44.1% year on year. Second-quarter operating revenue was 404 million yuan, up 15.9% year on year, while net profit attributable to the parent was 35.19 million yuan, down 29.7% year on year. The company said sales volume of its human rabies vaccine grew, but a value-added tax policy adjustment led to a slight decline in sales revenue, and net profit was affected by both lower operating revenue and higher costs and expenses.